Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis.

Zhao Y, Lee MH, Paderu P, Lee A, Jimenez-Ortigosa C, Park S, Mansbach RS, Shaw KJ, Perlin DS.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00425-18. doi: 10.1128/AAC.00425-18. Print 2018 Oct.

2.

A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.

Mansbach RS, Ludington E, Rogowski R, Kittrelle JP, Jochelson P.

Clin Ther. 2011 Jul;33(7):851-62. doi: 10.1016/j.clinthera.2011.05.092. Epub 2011 Jul 1.

PMID:
21722958
3.

The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential.

Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM.

Drug Alcohol Depend. 2010 Dec 1;112(3):173-7. doi: 10.1016/j.drugalcdep.2010.07.001.

PMID:
20817417
4.
5.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
6.

Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report.

Grudzinskas C, Balster RL, Gorodetzky CW, Griffiths RR, Henningfield JE, Johanson CE, Mansbach RS, McCormick CG, Schnoll SH, Strain EC, Wright C.

Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S77-82. Epub 2006 Mar 31.

PMID:
16580154
7.

Formulation considerations for the development of medications with abuse potential.

Mansbach RS, Moore RA Jr.

Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S15-22. Epub 2006 Feb 10.

PMID:
16472940
8.

3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.

Coe JW, Brooks PR, Wirtz MC, Bashore CG, Bianco KE, Vetelino MG, Arnold EP, Lebel LA, Fox CB, Tingley FD 3rd, Schulz DW, Davis TI, Sands SB, Mansbach RS, Rollema H, O'Neill BT.

Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.

PMID:
16171993
9.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT.

J Med Chem. 2005 May 19;48(10):3474-7.

PMID:
15887955
10.

Incorporating the assessment of abuse liability into the drug discovery and development process.

Mansbach RS, Feltner DE, Gold LH, Schnoll SH.

Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S73-85. Review.

PMID:
12759198
11.

Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone.

Mansbach RS, Carver J, Zorn SH.

Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):535-42.

PMID:
11509214
12.

Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine.

Mansbach RS, Chambers LK, Rovetti CC.

Psychopharmacology (Berl). 2000 Feb;148(3):234-42.

PMID:
10755736
13.

Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture.

Freedland CS, Mansbach RS.

Drug Alcohol Depend. 1999 May 3;54(3):183-94.

PMID:
10372792
14.

The role of monoamine neurotransmitter systems in the nicotine discriminative stimulus.

Mansbach RS, Rovetti CC, Freedland CS.

Drug Alcohol Depend. 1998 Oct 1;52(2):125-34.

PMID:
9800142
15.

Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition.

Mansbach RS, Brooks EW, Sanner MA, Zorn SH.

Psychopharmacology (Berl). 1998 Jan;135(2):194-200.

PMID:
9497025
16.

Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.

Chen YL, Mansbach RS, Winter SM, Brooks E, Collins J, Corman ML, Dunaiskis AR, Faraci WS, Gallaschun RJ, Schmidt A, Schulz DW.

J Med Chem. 1997 May 23;40(11):1749-54.

PMID:
9171885
17.

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

Mansbach RS, Brooks EN, Chen YL.

Eur J Pharmacol. 1997 Mar 26;323(1):21-6.

PMID:
9105872
18.

CP-135,807, a selective 5-HT1D agonist: effects in drug discrimination and punishment procedures in the pigeon.

Mansbach RS, Rovetti CC, Macor JE.

Psychopharmacology (Berl). 1996 Dec;128(3):313-9.

PMID:
8972551
19.

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD 3rd, Winston EN, Chen YL, Heym J.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10477-82.

20.

Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Mansbach RS, Rovetti CC, Winston EN, Lowe JA 3rd.

Psychopharmacology (Berl). 1996 Apr;124(4):315-22.

PMID:
8739546
21.

Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists.

Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E.

Behav Pharmacol. 1995 Aug;6(5 And 6):577-589.

PMID:
11224365
22.

Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys.

Mansbach RS, Jortani SA, Balster RL.

Eur J Pharmacol. 1995 Feb 14;274(1-3):167-73.

PMID:
7768269
23.

Lack of altered startle responding in rats following termination of self-administered or noncontingently infused cocaine.

Mansbach RS, Markou A, Patrick GA.

Pharmacol Biochem Behav. 1994 Jun;48(2):453-8.

PMID:
8090814
24.
25.

NPC 16377, a potent and selective sigma-ligand. II. Behavioral and neuroprotective profile.

Clissold DB, Pontecorvo MJ, Jones BE, Abreu ME, Karbon EW, Erickson RH, Natalie KJ Jr, Borosky S, Hartman T, Mansbach RS, et al.

J Pharmacol Exp Ther. 1993 May;265(2):876-86.

PMID:
8098765
26.

Effects of mazindol on behavior maintained or occasioned by cocaine.

Mansbach RS, Balster RL.

Drug Alcohol Depend. 1993 Jan;31(2):183-91.

PMID:
8436063
27.

Preclinical methods for the development of pharmacotherapies for cocaine abuse.

Balster RL, Mansbach RS, Gold L, Harris LS.

NIDA Res Monogr. 1992;119:160-4. No abstract available.

PMID:
1435972
28.

The acoustic startle response as a measure of behavioral dependence in rats.

Mansbach RS, Gold LH, Harris LS.

Psychopharmacology (Berl). 1992;108(1-2):40-6.

PMID:
1410145
29.

Potent substituted-3 beta-phenyltropane analogs of cocaine have cocaine-like discriminative stimulus effects.

Balster RL, Carroll FI, Graham JH, Mansbach RS, Rahman MA, Philip A, Lewin AH, Showalter VM.

Drug Alcohol Depend. 1991 Dec 31;29(2):145-51.

PMID:
1797525
30.

Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle.

Keith VA, Mansbach RS, Geyer MA.

Biol Psychiatry. 1991 Sep 15;30(6):557-66.

PMID:
1834231
31.

Effects of NMDA receptor ligands on sensorimotor gating in the rat.

Mansbach RS.

Eur J Pharmacol. 1991 Sep 4;202(1):61-6.

PMID:
1838498
32.

NMDA antagonists: lack of antipunishment effect in squirrel monkeys.

Mansbach RS, Willetts J, Jortani SA, Balster RL.

Pharmacol Biochem Behav. 1991 Aug;39(4):977-81.

PMID:
1837155
33.

Pharmacological specificity of the phencyclidine discriminative stimulus in rats.

Mansbach RS, Balster RL.

Pharmacol Biochem Behav. 1991 Aug;39(4):971-5.

PMID:
1837154
34.

Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine.

Mansbach RS, Geyer MA.

Psychopharmacology (Berl). 1991;105(2):162-8.

PMID:
1796122
35.

Intravenous self-administration of 4-methylaminorex in primates.

Mansbach RS, Sannerud CA, Griffiths RR, Balster RL, Harris LS.

Drug Alcohol Depend. 1990 Oct;26(2):137-44.

PMID:
2242714
36.

Startle response models of sensorimotor gating and habituation deficits in schizophrenia.

Geyer MA, Swerdlow NR, Mansbach RS, Braff DL.

Brain Res Bull. 1990 Sep;25(3):485-98. Review.

PMID:
2292046
37.

A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia.

Peng RY, Mansbach RS, Braff DL, Geyer MA.

Neuropsychopharmacology. 1990 Jun;3(3):211-8.

PMID:
2141986
38.

Temporal determinants of intravenous cocaine self-administration in rhesus monkeys'

Mansbach RS, Balster RL.

Behav Pharmacol. 1990;1(4):317-326.

PMID:
11175416
39.

Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats.

Davis M, Mansbach RS, Swerdlow NR, Campeau S, Braff DL, Geyer MA.

Psychopharmacology (Berl). 1990;102(1):1-4.

PMID:
2392496
40.

Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine.

Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL.

Psychopharmacology (Berl). 1990;100(3):413-6.

PMID:
2315438
41.

Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Mansbach RS, Geyer MA.

Neuropsychopharmacology. 1989 Dec;2(4):299-308.

PMID:
2692589
42.

Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.

Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE.

J Pharmacol Exp Ther. 1989 Sep;250(3):809-17.

PMID:
2476547
43.
44.

Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands.

Mansbach RS, Geyer MA.

Eur J Pharmacol. 1988 Nov 8;156(3):375-83.

PMID:
2975225
45.
46.

Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding.

Mansbach RS, Harrod C, Hoffmann SM, Nader MA, Lei Z, Witkin JM, Barrett JE.

J Pharmacol Exp Ther. 1988 Jul;246(1):114-20.

PMID:
2455786
47.

Dopaminergic stimulation disrupts sensorimotor gating in the rat.

Mansbach RS, Geyer MA, Braff DL.

Psychopharmacology (Berl). 1988;94(4):507-14.

PMID:
3131796
48.

Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons.

Witkin JM, Mansbach RS, Barrett JE, Bolger GT, Skolnick P, Weissman B.

J Pharmacol Exp Ther. 1987 Dec;243(3):970-7.

PMID:
2891840
49.

Discriminative stimulus properties of buspirone in the pigeon.

Mansbach RS, Barrett JE.

J Pharmacol Exp Ther. 1987 Feb;240(2):364-9.

PMID:
3806400
50.

Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms.

Barrett JE, Witkin JM, Mansbach RS, Skolnick P, Weissman BA.

J Pharmacol Exp Ther. 1986 Sep;238(3):1009-13.

PMID:
2875168

Supplemental Content

Loading ...
Support Center